Dasabuvir -- Benefit Assessment According to §35a Social Code Book V [Internet].

The aim of the present report is to assess the added benefit of the drug dasabuvir in comparison with dual therapy of peginterferon and ribavirin (PEG + RBV) or triple therapy of telaprevir, peginterferon and ribavirin (TVR + PEG + RBV) as appropriate comparator therapy (ACT) in patients with chronic hepatitis C (CHC) genotype 1.

http://ift.tt/2seyu5L